Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Monday, June 30, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2025 (2025-06-30): -440.30%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Jupiter Neurosciences, Inc.
Market Cap
$1.26M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.21M
Return on Equity (ROE)
-200.63%
TTM Avg
-312.18%
3Y Avg
-122.70%
5Y Avg
-56.14%
Market Cap
$1.33M
Return on Equity (ROE)
-114.48%
TTM Avg
-127.66%
3Y Avg
-155.08%
5Y Avg
-465.16%
Market Cap
$1.35M
Return on Equity (ROE)
-111.51%
TTM Avg
-753.43%
3Y Avg
-507.39%
5Y Avg
-356.28%
Market Cap
$1.15M
Return on Equity (ROE)
N/A
TTM Avg
558.67%
3Y Avg
54.46%
5Y Avg
-8.27%
Market Cap
$1.40M
Return on Equity (ROE)
-253.57%
TTM Avg
334.28%
3Y Avg
134.39%
5Y Avg
95.16%
Market Cap
$1.10M
Return on Equity (ROE)
-11.85%
TTM Avg
-6.20%
3Y Avg
47.36%
5Y Avg
47.36%
Market Cap
$1.43M
Return on Equity (ROE)
-124.97%
TTM Avg
-62.14%
3Y Avg
-63.41%
5Y Avg
-579.67%
Market Cap
$1.45M
Return on Equity (ROE)
-32.05%
TTM Avg
-197.10%
3Y Avg
-44.98%
5Y Avg
-69.38%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jupiter Neurosciences, Inc. (JUNS) | $1.26M | N/A | N/A | N/A | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.21M | -200.63% | -312.18% | -122.70% | -56.14% |
| NewcelX Ltd. (NCEL)vs › | $1.33M | -114.48% | -127.66% | -155.08% | -465.16% |
| Genprex, Inc. (GNPX)vs › | $1.35M | -111.51% | -753.43% | -507.39% | -356.28% |
| IM Cannabis Corp. (IMCC)vs › | $1.15M | N/A | 558.67% | 54.46% | -8.27% |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.40M | -253.57% | 334.28% | 134.39% | 95.16% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | -11.85% | -6.20% | 47.36% | 47.36% |
| NEXGEL, Inc. (NXGL)vs › | $1.43M | -124.97% | -62.14% | -63.41% | -579.67% |
| INVO Fertility, Inc. (IVF)vs › | $1.45M | -32.05% | -197.10% | -44.98% | -69.38% |
| Clearmind Medicine Inc. (CMND)vs › | $1.07M | -57.87% | -222.45% | -164.72% | -135.78% |
ROE
N/A
ROA
-247.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-06-30 | -440.30% |
| 2025-03-31 | -108.80% |
| 2024-12-31 | -58.48% |
